Table 5 Univariate and multivariate Cox analysis for PFS

Gender

0.785

0.883

 Male

Reference

Reference

 Female

0.879 (0.568–1.457)

1.102 (0.487–1.569)

Age (years)

0.415

0.845

 < 18

Reference

Reference

 ≥ 18

1.254 (0.742–2.124)

1.126 (0.974–1.951)

Tumor location

0.576

0.451

 Extremities

Reference

1

 Non-extremities

1.375 (0.825–2.273)

1.255 (0.998–2.989)

Tumor size (cm)

0.021

0.165

 < 10.5

Reference

Reference

 ≥ 10.5

2.147 (1.126–3.589)

1.362 (1.079–4.532)

Histological type

0.457

0.752

 Well-differentiated

Reference

Reference

 Poorly differentiated

1.541 (0.856–3.124)

1.336 (1.0719–3.257)

Enneking stage

< 0.001

< 0.001

 I/II

Reference

Reference

 III

4.577 (1.036–12.539)

6.457 (1.324–10.987)

Pathological fracture

0.341

0.542

 No

Reference

Reference

 Yes

1.243 (0.756–3.493)

1.322 (0.893–5.786)

Local recurrence

< 0.001

< 0.001

 No

Reference

Reference

 Yes

5.467 (1.095–9.852)

6.991 (2.048–11.548)

Metastasis

< 0.001

< 0.001

 No

Reference

Reference

 Yes

6.678 (3.589–10.679)

7.895 (4.470–12.907)

Neoadjuvant CT

0.688

0.785

 No

Reference

Reference

 Yes

0.842 (0.413–1.759)

0.903 (0.378–2.235)

NLR

< 0.001

< 0.001

 Low (≤ 2.96)

Reference

Reference

 High (> 2.96)

4.517 (1.657–8.689)

4.652 (1.329–9.547)

LMR

0.003

0.062

 Low (≤ 4.44)

Reference

Reference

 High (> 4.44)

0.751 (0.556–1.579)

0.876 (0.657–1.322)

Albumin

0.046

0.257

 Low (< 4 mg/dL)

Reference

Reference

 High (≥ 4 mg/dL)

0.854 (0.687–2.211)

0.859 (0.789–1.457)

TC

0.142

0.457

 Low (≤ 180 mg/dL)

Reference

Reference

 High (> 180 mg/dL)

0.984 (0.568–1.788)

1.054 (0.891–2.014)

NPS Group

 1

Reference

Reference

 2

5.672 (1.254–10.003)

< 0.001

5.272 (1.017–11.485)

< 0.001

 3

7.841 (1.029–11.565)

< 0.001

6.783 (1.234–10.575)

< 0.001